GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe a...

GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe aplastic anaemia  GSK

Generic Medicine OKd by Europe for Thrombocytopenia With HCV - Medscape

Generic Medicine OKd by Europe for Thrombocytopenia With HCV  Medscape

Sino Bio's Revolade Generic Approved in China - NAVLIN DAILY

Sino Bio's Revolade Generic Approved in China  NAVLIN DAILY

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designati...

FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication  Novartis

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia - koreabiomed.com

Health ministry to reimburse Novartis’ Revolade treating severe aplastic anemia  koreabiomed.com

NICE thumbs-up for Revolade - Pharmafile

NICE thumbs-up for Revolade  Pharmafile

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia - The New England Journal of Med...

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia  The New England Journal of Medicine

Novartis bags EU approvals for three ex-GSK drugs - PMLiVE

Novartis bags EU approvals for three ex-GSK drugs  PMLiVE

NICE says yes to Grifols' Tavlesse for rare blood disorder ITP - pharmaphorum

NICE says yes to Grifols' Tavlesse for rare blood disorder ITP  pharmaphorum

Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Re...

Regulatory Update – GSK announces submissions in the EU & US for new indications for Promacta®/Revolade  GSK

Novartis' patent on eltrombopag olamine upheld by Delhi High Court - The Pharma Letter

Novartis' patent on eltrombopag olamine upheld by Delhi High Court  The Pharma Letter

Novartis: Blood Disease Drugs Jakavi, Revolade Show Positive Study Results - finchannel

Novartis: Blood Disease Drugs Jakavi, Revolade Show Positive Study Results  finchannel

New hope for ITP patients dashed by high drug cost - CBC

New hope for ITP patients dashed by high drug cost  CBC

Novartis’ Revolade proved effective for seniors - koreabiomed.com

Novartis’ Revolade proved effective for seniors  koreabiomed.com

GSK guilty of off-label promotion - Pharmafile

GSK guilty of off-label promotion  Pharmafile

GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepat...

GSK receives positive CHMP opinion for REVOLADE in thrombocytopenia associated with chronic hepatitis C infection  GSK

TLV Decides High-Cost Protection Inclusion for Doptelet for ITP - NAVLIN DAILY

TLV Decides High-Cost Protection Inclusion for Doptelet for ITP  NAVLIN DAILY

GSK’s Promacta extends US licence - Pharmafile

GSK’s Promacta extends US licence  Pharmafile

GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic sy...

GSK announces the start of a phase III study with eltrombopag in patients with myelodysplastic syndromes  GSK

GSK announces submission to U.S. regulatory authorities for Promacta™ (eltrombopag) for severe ap...

GSK announces submission to U.S. regulatory authorities for Promacta™ (eltrombopag) for severe aplastic anaemia  GSK

Govt to fund drug for rare blood disorder - NZ Herald

Govt to fund drug for rare blood disorder  NZ Herald